Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 404,25 € (-0,19 %). Medianen er 405,59 € (+0,15 %).
| Køb |
19 |
| Behold |
16 |
| Sælg |
2 |
Nyheder Til nyhedsfeedet
Waters seen by Morgan Stanley as best positioned by China's new lab price framework
Morgan Stanley rates Waters as a winner from China’s final pricing framework for clinical laboratory services due to its position in mass spectrometry and more complex microbiological workflows. The framework, published by the National Healthcare Security Administration, retains a method-neutral structure, provides differentiated treatment and specific add-ons for mass spectrometry, and sets out more detailed rules for microbiology services. Danaher, Beckman Coulter and Thermo Fisher will be affected differently: Danaher faces limited risks to parts of its business, Beckman Coulter is under pressure in routine chemistry and immunoassays, and Thermo Fisher is less affected because of its portfolio structure and recent sales. » Mere på de.investing.com
Waters Corporation reaches 52‑week high at $420.3
Shares of Waters Corporation rose to a 52‑week high of $420.3 and are currently trading at $420.77, with a market capitalization of $41.3 billion. Year‑to‑date the stock is up 44.4%. In the second quarter the company beat expectations with adjusted earnings of $3.05 per share (estimate $3.01) and revenue of $1.64 billion (estimate $1.62 billion), but it faces currency headwinds and integration challenges. TD Cowen has upgraded the stock to Buy and raised the price target to $475, while analysts also warn of potential overvaluation. » Mere på de.investing.com
Waters beats Q2 forecasts and raises full-year outlook, stock slightly down premarket
Waters reported adjusted EPS of $3.05 for Q2 (expectation $3.01) and revenue of $1.645 billion (expectation $1.62 billion). Management raised the full-year guidance for organic revenue growth to 7–9% and adjusted EPS to $14.45–14.65, supported by cost reductions, price increases and product launches. Premarket the stock fell about 1.3% as investors weighed currency effects, acquisition-related charges and the complexity of integrating acquired businesses. Risks remain from currency headwinds, integration efforts and execution of planned price increases. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | juli 2026 | YoY |
|---|---|---|
| Omsætning | 1,44 mia. | 118,42 % |
| Bruttofortjeneste | 641,45 mio. | 67,08 % |
| Nettoresultat | -118,85 mio. | 194,68 % |
| EBITDA | 187,89 mio. | 9,64 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 39,67 mia. € |
Antal aktier | 98,19 mio. |
Højeste/laveste i 52 uger | 414,83 € - 252,06 € |
| Udbytte | Nej |
Beta | 1,15 |
P/E (PE Ratio) | 112,74 |
PEG (PEG Ratio) | -1,76 |
K/I (PB Ratio) | 2,93 |
P/S (PS Ratio) | 9,58 |
Virksomhedsprofil
Waters Corporation, et virksomhed inden for specialiseret måling, leverer analytiske arbejdsgange i Asien, Amerika og Europa. Virksomheden opererer gennem to segmenter, Waters og TA. Selskabet designer, fremstiller, sælger og servicerer high- og ultra-performance væskekromatografi samt massespektrometri (MS)-teknologisystemer og støtteprodukter, herunder kromatografikolonner, andre forbrugsprodukter og serviceplaner efter garantiperioden. Det designer, fremstiller, sælger og servicerer også instrumenter til termisk analyse, reometri og kalorimetri; og udvikler og leverer softwarebaserede produkter, der interagerer med dens instrumenter, samt andre producenters instrumenter. Dets MS-teknologiinstrumenter anvendes i lægemiddelopdagelse og -udvikling, herunder afprøvning i kliniske forsøg, analyse af proteiner i sygdomsprocesser, analyse af fødevaresikkerhed og miljøtest. Virksomheden tilbyder instrumenter til termisk analyse, reometri og kalorimetri, som anvendes til at forudsige egnethed og stabilitet af finkemikalier, lægemidler, vand, polymerer, metaller og viskøse væsker til forskellige industrielle produkter, forbrugsvarer og sundhedsprodukter, samt til forskning inden for life science. Dets produkter anvendes af kunder inden for life science, farmaceutisk industri, biokemi, industri, fødevaresikkerhed, miljø, akademi og offentlige myndigheder, som arbejder med forskning og udvikling, kvalitetssikring og andre laboratorieapplikationer. Waters Corporation blev grundlagt i 1958 og har hovedsæde i Milford, Massachusetts.
| Navn | Waters |
| CEO | Udit Batra |
| Hjemsted | Milford,
ma USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Bioteknologi |
| Børsnotering | 17.11.1995 |
| Medarbejdere | 7.900 |
Tickersymboler
| Børs | Symbol |
|---|---|
NYSE | WAT |
London Stock Exchange | 0LTI.L |
Frankfurt | WAZ.F |
Düsseldorf | WAZ.DU |
London | 0LTI.L |
SIX | WAZ.SW |
München | WAZ.MU |